secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001437749-25-010358
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton out-licenses international rights to Increlex to Esteve for €4M upfront
----------------------------------------------------------------------------

- Esteve pays €4M upfront; license runs up to ten years with option to buy international rights for up to €6M.
- Eton supplies Increlex at a fixed transfer price; no change to expected $80M annual revenue run rate exiting 2025.
- Deal lets Eton focus on three rare-disease product launches planned in the U.S. for 2025.
- Eton eliminates need for significant ex-U.S. commercialization infrastructure investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925010358/0001437749-25-010358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925010358/eton20250321_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-010358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer